Galcanezumab (Emgality)
What studies of Galcanezumab (Emgality) found
At a glance, by condition
Long COVID: C Might help, very uncertain
Based on the strongest evidence, studies with no comparison group (very low certainty), for pain.
1 outcome rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: Galcanezumab (Emgality) might help some people with long COVID, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- Galcanezumab (Emgality) · Long COVID is hereCMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- DLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
Long COVID
Pain1 study · 1 (few people) person took Galcanezumab (Emgality) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.
Studies with no comparison group1 in the study · after the fourth month's dose of galcanezumab · Loading dose (240 mg), Monthly, 120 mg of CGRP mAb treatment was planned during follow-up (few people)
Pain improved.
The evidence is very uncertain about the effect of galcanezumab (Emgality) on pain in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (1 in all)
- Not all results were tested against chance
See the 1 study
-
- People in the study
- 1 in the study
- Dose
- Loading dose (240 mg), Monthly, 120 mg of CGRP mAb treatment was planned during follow-up
- Outcome
- headache intensity and frequency
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Side effects
No study of this treatment alone reported side effects we could read.
Doses studied
What researchers used, as the papers print it; not a recommendation.
- 1Start
240 mg at the start
- 2Top dose
Most often 240 mg (1 of 1 studies)
Doses across 1 study
240 to 240 mg.
Each study’s dose, as printed
- Loading dose (240 mg), Monthly, 120 mg of CGRP mAb treatment was planned during follow-up Is Persistent Post-COVID Headache Associated With Protein-Protein Interactions Between Antibodies Against Viral Spike Protein and CGRP Receptor?: A Case Report. (2022)
All papers
- Is Persistent Post-COVID Headache Associated With Protein-Protein Interactions Between Antibodies Against Viral Spike Protein and CGRP Receptor?: A Case Report.2022 · case report · 1 in the study
Summary
This case report describes one 44-year-old woman with persistent post-COVID headache after a mild COVID-19 infection at the beginning of August 2021. She first visited the authors' headache outpatient clinic at the end of September 2021. There was no comparison group; the report describes before-and-after observations in the same patient. She received subcutaneous galcanezumab, a CGRP monoclonal antibody: a loading dose of 240 mg, a second dose of 120 mg, and monthly 120 mg planned during follow-up, with follow-up after the fourth month's dose. Headache intensity was measured with a visual analog scale out of 10, and headache frequency was also described. According to the report, her headaches decreased in intensity and frequency within 2 days; her headache decreased to 2-3 out of 10. During follow-up, intensity increased gradually to 5 out of 10 in 3 weeks. After the second dose of 120 mg, intensity decreased to 1–2 out of 10 within 2 days again, and she was headache-free when last seen after the fourth month's dose of galcanezumab. No side effects were reported. The authors state that large-scale randomized controlled trials are required to study the efficacy of CGRP antagonist or therapy with a CGRP mAb in treating post-COVID headaches.